echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Clinical trial of Taletrectinib in the treatment of NTRK fusion solid tumors completed the first patient administration

    Clinical trial of Taletrectinib in the treatment of NTRK fusion solid tumors completed the first patient administration

    • Last Update: 2021-06-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Innovent announced today that the second phase basket trial of taletrectinib in the treatment of NTRK fusion solid tumors has completed the first patient administration (NCT04617054)
    .

    It is understood that Taletrectinib is a new generation of tyrosine kinase inhibitor (TKI) under development
    .
    The preliminary results of the Phase II clinical trial of Taletrecinib in ROS1 fusion with non-small cell lung cancer have shown good efficacy and safety

    .

    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.